Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use

Author:

Olney Katie B.1ORCID,Thomas Jenni K.1ORCID,Johnson Wes M.1ORCID

Affiliation:

1. Department of Pharmacy Services University of Kentucky HealthCare Lexington Kentucky USA

Abstract

AbstractAntimicrobial resistance continues to surmount increasing concern globally, and treatment of difficult‐to‐treat (DTR) Pseudomonas aeruginosa, carbapenem‐resistant (CR) Acinetobacter baumannii (CRAB), and CR Enterobacterales (CRE) remains a challenge for clinicians. Although previously rare, the incidence of multidrug‐resistant (MDR) and CR infections in pediatric patients has increased drastically in the last decade and is associated with increased morbidity and mortality. To combat this issue, 14 novel antibiotics, including three β‐lactam/novel β‐lactamase inhibitor combinations (βL‐βLIs) and two novel β‐lactams (βLs), have received approval from the United States Food and Drug Administration since 2010. Improving clinician understanding of the utility of these novel therapies is imperative to improve judicious decision‐making and prevent societal regression to a pre‐penicillin era. In this review, we summarize the pharmacokinetic/pharmacodynamic (PK/PD) properties, clinical efficacy and safety data, dosing considerations, and subsequent role in therapy for ceftazidime‐avibactam (CAZ‐AVI), meropenem‐vaborbactam (MER‐VAB), imipenem‐cilastatin‐relebactam (IMI‐REL), ceftolozane‐tazobactam (TOL‐TAZ), and cefiderocol in pediatric patients.

Publisher

Wiley

Subject

Pharmacology (medical)

Reference116 articles.

1. O'neillJ.Antimicrobial resistance: tackling a crisis for the health and wealth of nations.2014.

2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

3. Multidrug‐ and carbapenem‐resistant Pseudomonas aeruginosa in children, United States, 1999–2012;Logan LK;J Pediatric Infect Dis Soc,2017

4. Carbapenem-ResistantEnterobacteriaceaein Children, United States, 1999–2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3